华兰疫苗(301207) - 2025 Q3 - 季度财报

Financial Performance - Revenue for Q3 2025 was CNY 746,025,122.57, a decrease of 19.07% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 111,511,443.25, down 53.94% year-on-year[5] - Basic earnings per share decreased by 53.64% to CNY 0.1874[5] - Total operating revenue decreased to ¥805,986,896.84 from ¥957,363,018.62, representing a decline of approximately 15.8% year-over-year[18] - Net profit for the period was ¥132,308,600.05, down from ¥267,359,727.86, indicating a decrease of about 50.6% compared to the previous year[19] - Operating profit fell to ¥139,351,616.48 from ¥305,871,419.40, a decrease of approximately 54.5% year-over-year[19] - The basic earnings per share decreased to ¥0.2224 from ¥0.4463, reflecting a decline of about 50%[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,179,369,720.73, a decrease of 4.57% from the end of the previous year[5] - Total assets decreased to ¥7,179,369,720.73 from ¥7,523,255,843.58, a reduction of about 4.6%[18] - Total liabilities slightly decreased to ¥1,504,528,077.23 from ¥1,510,111,321.68, showing a decline of approximately 0.4%[18] - The company's equity attributable to shareholders decreased to ¥5,674,841,643.50 from ¥6,013,144,521.90, a drop of about 5.6%[18] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 181,964,118.25, down 48.11% year-on-year[5] - Operating cash flow for the current period is ¥181,964,118.25, a decrease of 48.0% compared to ¥350,644,555.60 in the previous period[20] - The company reported cash received from operating activities totaling ¥865,490,687.86, down 34.1% from ¥1,314,347,439.35[20] - The company’s cash flow from operating activities was impacted by a significant reduction in cash received from sales, which totaled ¥840,417,243.67, down 35.2% from ¥1,295,544,904.55[20] - Cash and cash equivalents at the end of the period increased to ¥854,136,140.42, up from ¥531,251,202.49 in the previous period[21] - The company experienced a 100% reduction in short-term borrowings, repaying CNY 300,183,333.33 during the period[8] Expenses - R&D expenses increased by 38.84% to CNY 111,781,220.66 due to higher clinical trial costs[8] - Management expenses decreased by 36.43% to CNY 52,945,493.02, primarily due to reduced inventory write-offs[8] - Research and development expenses increased to ¥111,781,220.66, up from ¥80,510,272.88, reflecting a growth of approximately 38.7% year-over-year[18] - Cash paid for purchasing goods and services was ¥125,460,323.97, a decrease of 41.6% compared to ¥214,925,416.84[20] Shareholder Information - Total number of common shareholders at the end of the reporting period was 17,147[10] - The largest shareholder, Hualan Biological Engineering, holds 67.38% of shares, totaling 405,000,000 shares[10] - The company has a repurchase account holding 6,027,467 shares, representing 1.00% of total shares, ranking it as the 5th largest shareholder[11] - The top two shareholders are identified as acting in concert, indicating a potential influence on company decisions[11] - The company has no preferred shareholders or changes in restricted shares during the reporting period[12] Other Financial Metrics - The weighted average return on equity was 1.85%, down 2.06% from the previous year[5] - Deferred income tax assets decreased to ¥204,762,701.06 from ¥212,727,411.11, a reduction of approximately 3.5%[18] - Other non-current assets decreased to ¥1,174,869,156.97 from ¥1,214,773,182.18, indicating a decline of about 3.3%[18] Investment Activities - Investment cash inflow decreased significantly to ¥6,262,680,030.87 from ¥14,744,165,919.04, representing a decline of 57.6%[20] - Net cash flow from investment activities improved to ¥489,074,624.74, compared to a negative cash flow of ¥33,805,690.23 in the previous period[21] - The company did not receive any cash from new investments during the current period, contrasting with ¥16,281,000.00 received in the previous period[21] Audit Status - The company’s financial report for the third quarter was not audited[22]